论文部分内容阅读
报告原始细胞过多的难治性贫血(RAEB)、转化中的RAEB(RAEB-T)和慢性粒单细胞性白血病(CMML)25例,随机分成A及B组,分别采用诱导分化剂或诱导分化剂加胎肝细胞输注(FLI)治疗,缓解率分别为41.6％(5/12)和69.3％(9/13)。骨髓病理及染色体复查均有不同程度恢复,尤以B组较为突出,且其疗效明显高于A组,死亡率却较低。疗效高低似乎与疗程长短,有无附加支持疗法和积极防治感染、出血等并发症密切相关,多次FLI可能有助于诱导分化和促进造血功能的恢复,利于患者渡过感染与出血等危险时期。
Reported 25 cases of RAEB, RAEB-T and CMML were randomly divided into A and B groups and induced with differentiation inducer Differentiation agent plus fetal liver cell infusion (FLI) treatment, the response rates were 41.6% (5/12) and 69.3% (9/13). Bone marrow pathology and chromosomal review have varying degrees of recovery, especially in the B group is more prominent, and its efficacy was significantly higher than the A group, the mortality rate is low. The level of efficacy appears to be closely related to the duration of treatment, the presence or absence of additional supportive therapy and active prevention and treatment of infection, bleeding and other complications. Multiple FLI may help to induce differentiation and promote the recovery of hematopoietic function, which will benefit patients at risk of infection and bleeding .